{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:02:01Z","timestamp":1786982521014,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Chengdu Medical Research Project of Chengdu Health and Family Planning Commission","award":["2022177"],"award-info":[{"award-number":["2022177"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03775-7","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T13:45:35Z","timestamp":1767620735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The value of DNA repair gene and TP53 co-mutation in predicting the response of non-small cell lung cancer to immunotherapy"],"prefix":"10.1007","volume":"17","author":[{"given":"Bin","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunzhi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"1","key":"3775_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.36469\/jheor.2022.32983","volume":"9","author":"G Gourzoulidis","year":"2022","unstructured":"Gourzoulidis G, Zisimopoulou O, Boubouchairopoulou N, Michailidi C, Lowry C, Tzanetakos C, et al. Cost-effectiveness analysis of lorlatinib in patients previously treated with anaplastic lymphoma kinase inhibitors for non-small cell lung cancer in Greece. J Health Econ Outcomes Res. 2022;9(1):50\u20137. https:\/\/doi.org\/10.36469\/jheor.2022.32983.","journal-title":"J Health Econ Outcomes Res"},{"key":"3775_CR2","doi-asserted-by":"publisher","DOI":"10.2174\/1874467217666230721123554","volume":"17","author":"XJ Qian","year":"2024","unstructured":"Qian XJ, Wang JW, Liu JB, Yu X. The mediating role of miR-451\/ETV4\/MMP13 signalling axis on epithelial-mesenchymal transition in promoting non-small cell lung cancer progression. Curr Mol Pharmacol. 2024;17:e210723218988. https:\/\/doi.org\/10.2174\/1874467217666230721123554.","journal-title":"Curr Mol Pharmacol"},{"key":"3775_CR3","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429269383231119062233","volume":"17","author":"A Ullah","year":"2024","unstructured":"Ullah A, Razzaq A, Alfaifi MY, Elbehairi SEI, Menaa F, Ullah N, et al. Sanguinarine attenuates lung cancer progression via oxidative stress-induced cell apoptosis. Curr Mol Pharmacol. 2024;17:e18761429269383. https:\/\/doi.org\/10.2174\/0118761429269383231119062233.","journal-title":"Curr Mol Pharmacol"},{"issue":"2","key":"3775_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/1874467215666220329212300","volume":"16","author":"Y Cai","year":"2023","unstructured":"Cai Y, Sheng Z, Dong Z, Wang J. EGFR inhibitor CL-387785 suppresses the progression of lung adenocarcinoma. Curr Mol Pharmacol. 2023;16(2):211\u20136. https:\/\/doi.org\/10.2174\/1874467215666220329212300.","journal-title":"Curr Mol Pharmacol"},{"issue":"1","key":"3775_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-020-00940-z","volume":"13","author":"Y Chen","year":"2020","unstructured":"Chen Y, Gao M, Huang Z, Yu J, Meng X. SBRT combined with PD-1\/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. J Hematol Oncol. 2020;13(1):105. https:\/\/doi.org\/10.1186\/s13045-020-00940-z.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"3775_CR6","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jtho.2017.04.014","volume":"12","author":"X Gong","year":"2017","unstructured":"Gong X, Li X, Jiang T, Xie H, Zhu Z, Zhou F, et al. Combined radiotherapy and anti-PD-L1 antibody synergistically enhances antitumor effect in non-small cell lung cancer. J Thorac Oncol. 2017;12(7):1085\u201397. https:\/\/doi.org\/10.1016\/j.jtho.2017.04.014.","journal-title":"J Thorac Oncol"},{"key":"3775_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111239","volume":"126","author":"J Zhou","year":"2024","unstructured":"Zhou J, Shi F, Luo X, Lei B, Shi Z, Huang C, et al. The persistence and antitumor efficacy of CAR-T cells are modulated by tonic signaling within the CDR. Int Immunopharmacol. 2024;126:111239. https:\/\/doi.org\/10.1016\/j.intimp.2023.111239.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"3775_CR8","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1186\/s12885-020-07690-8","volume":"20","author":"WM Brueckl","year":"2020","unstructured":"Brueckl WM, Ficker JH, Zeitler G. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). BMC Cancer. 2020;20(1):1185. https:\/\/doi.org\/10.1186\/s12885-020-07690-8.","journal-title":"BMC Cancer"},{"key":"3775_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1085632","volume":"12","author":"Y Chang","year":"2023","unstructured":"Chang Y, Huang Z, Quan H, Li H, Yang S, Song Y, et al. Construction of a DNA damage repair gene signature for predicting prognosis and immune response in breast cancer. Front Oncol. 2023;12:1085632. https:\/\/doi.org\/10.3389\/fonc.2022.1085632.","journal-title":"Front Oncol"},{"issue":"20","key":"3775_CR10","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.7150\/jca.31062","volume":"10","author":"C Jinjia","year":"2019","unstructured":"Jinjia C, Xiaoyu W, Hui S, Wenhua L, Zhe Z, Xiaodong Z, et al. The use of DNA repair genes as prognostic indicators of gastric cancer. J Cancer. 2019;10(20):4866\u201375. https:\/\/doi.org\/10.7150\/jca.31062.","journal-title":"J Cancer"},{"issue":"15","key":"3775_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158281","volume":"22","author":"K Kalavska","year":"2021","unstructured":"Kalavska K, Sestakova Z, Mlcakova A, Kozics K, Gronesova P, Hurbanova L, et al. Are changes in the percentage of specific leukocyte subpopulations associated with endogenous DNA damage levels in testicular cancer patients? Int J Mol Sci. 2021;22(15):8281. https:\/\/doi.org\/10.3390\/ijms22158281.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3775_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11033-023-09097-7","volume":"51","author":"KL Zhu","year":"2024","unstructured":"Zhu KL, Su F, Yang JR, Xiao RW, Wu RY, Cao MY, et al. TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress. Mol Biol Rep. 2024;51(1):205. https:\/\/doi.org\/10.1007\/s11033-023-09097-7.","journal-title":"Mol Biol Rep"},{"issue":"5","key":"3775_CR13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/s41418-022-00996-z","volume":"29","author":"AF Thomas","year":"2022","unstructured":"Thomas AF, Kelly GL, Strasser A. Of the many cellular responses activated by TP53, which ones are critical for tumour suppression? Cell Death Differ. 2022;29(5):961\u201371. https:\/\/doi.org\/10.1038\/s41418-022-00996-z.","journal-title":"Cell Death Differ"},{"issue":"5","key":"3775_CR14","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41418-022-00962-9","volume":"29","author":"Z Wang","year":"2022","unstructured":"Wang Z, Strasser A, Kelly GL. Should mutant TP53 be targeted for cancer therapy? Cell Death Differ. 2022;29(5):911\u201320. https:\/\/doi.org\/10.1038\/s41418-022-00962-9.","journal-title":"Cell Death Differ"},{"key":"3775_CR15","doi-asserted-by":"publisher","first-page":"117955492311849","DOI":"10.1177\/11795549231184918","volume":"17","author":"L Zhu","year":"2023","unstructured":"Zhu L, Zhou D, Chen Y, Guo T, Chen W, Pan X. Correlation analysis of the TP53 mutation with clinical characteristics in the prognosis of non-small cell lung cancer. Clin Med Insights Oncol. 2023;17:11795549231184918. https:\/\/doi.org\/10.1177\/11795549231184918.","journal-title":"Clin Med Insights Oncol"},{"issue":"3","key":"3775_CR16","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1016\/j.cllc.2018.12.009","volume":"20","author":"P Tomasini","year":"2019","unstructured":"Tomasini P, Mascaux C, Jao K, Labbe C, Kamel-Reid S, Stockley T, et al. Effect of coexisting KRAS and TP53 mutations in patients treated with chemotherapy for non-small-cell lung cancer. Clin Lung Cancer. 2019;20(3):e338\u201345. https:\/\/doi.org\/10.1016\/j.cllc.2018.12.009.","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"3775_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041047","volume":"9","author":"M Canale","year":"2020","unstructured":"Canale M, Petracci E, Delmonte A, Bronte G, Chiadini E, Ludovini V, et al. Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs. J Clin Med. 2020;9(4):1047. https:\/\/doi.org\/10.3390\/jcm9041047.","journal-title":"J Clin Med"},{"issue":"12","key":"3775_CR18","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","volume":"23","author":"ZY Dong","year":"2017","unstructured":"Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2017;23(12):3012\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2554.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"3775_CR19","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1158\/1078-0432.CCR-22-3413","volume":"29","author":"B Ricciuti","year":"2023","unstructured":"Ricciuti B, Elkrief A, Alessi J, Wang X, Li Y, Gupta H, et al. Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer. Clin Cancer Res. 2023;29(13):2540\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3413.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"3775_CR20","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1158\/1078-0432.CCR-19-3529","volume":"26","author":"B Ricciuti","year":"2020","unstructured":"Ricciuti B, Recondo G, Spurr LF, Li YY, Lamberti G, Venkatraman D, et al. Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer. Clin Cancer Res. 2020;26(15):4135\u201342. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3529.","journal-title":"Clin Cancer Res"},{"key":"3775_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1240068","volume":"14","author":"F Yang","year":"2023","unstructured":"Yang F, Wei W, Li G, Lan Q, Liu X, Gao L, et al. A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score. Front Genet. 2023;14:1240068. https:\/\/doi.org\/10.3389\/fgene.2023.1240068.","journal-title":"Front Genet"},{"key":"3775_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1028132","volume":"12","author":"S Zhang","year":"2022","unstructured":"Zhang S, Sun Q, Cai F, Li H, Zhou Y. Local therapy treatment conditions for oligometastatic non-small cell lung cancer. Front Oncol. 2022;12:1028132. https:\/\/doi.org\/10.3389\/fonc.2022.1028132.","journal-title":"Front Oncol"},{"key":"3775_CR23","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2023.0033","author":"J Wang","year":"2023","unstructured":"Wang J, Jiang L, Shang Z, Ye Z, Yuan D, Cui X. A prognostic model for prostate cancer patients based on two DNA damage response mutation-related immune genes. Cancer Biother Radiopharm. 2023. https:\/\/doi.org\/10.1089\/cbr.2023.0033.","journal-title":"Cancer Biother Radiopharm"},{"issue":"15suppl","key":"3775_CR24","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1200\/JCO.2021.39.15_suppl.2611","volume":"39","author":"W Nie","year":"2021","unstructured":"Nie W, Zhong H, Wen F, Zhang D, Chen S, Han B. Therapeutic effect of DDR pathway with different functional annotations for immune checkpoint inhibitor. J Clin Oncol. 2021;39(15suppl):2611\u20132611. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.2611.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3775_CR25","doi-asserted-by":"publisher","first-page":"e002279","DOI":"10.1136\/jitc-2020-002279","volume":"9","author":"S Isoyama","year":"2021","unstructured":"Isoyama S, Mori S, Sugiyama D, Kojima Y, Tada Y, Shitara K, et al. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. J Immunother Cancer. 2021;9(8):e002279. https:\/\/doi.org\/10.1136\/jitc-2020-002279.","journal-title":"J Immunother Cancer"},{"key":"3775_CR26","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1017\/erm.2020.3","volume":"22","author":"HL Smith","year":"2020","unstructured":"Smith HL, Southgate H, Tweddle DA, Curtin NJ. DNA damage checkpoint kinases in cancer. Expert Rev Mol Med. 2020;22:e2. https:\/\/doi.org\/10.1017\/erm.2020.3.","journal-title":"Expert Rev Mol Med"},{"issue":"1","key":"3775_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3892\/etm.2023.12321","volume":"27","author":"Y Lin","year":"2023","unstructured":"Lin Y, Jin X. Effect of ubiquitin protease system on DNA damage response in prostate cancer (Review). Exp Ther Med. 2023;27(1):33. https:\/\/doi.org\/10.3892\/etm.2023.12321.","journal-title":"Exp Ther Med"},{"issue":"8","key":"3775_CR28","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14656566.2021.1876662","volume":"22","author":"SY Oh","year":"2021","unstructured":"Oh SY, Rahman S, Sparano JA. Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer. Expert Opin Pharmacother. 2021;22(8):981\u20131003. https:\/\/doi.org\/10.1080\/14656566.2021.1876662.","journal-title":"Expert Opin Pharmacother"},{"key":"3775_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106529","volume":"186","author":"X Peng","year":"2022","unstructured":"Peng X, Pan W, Jiang F, Chen W, Qi Z, Peng W, et al. Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy. Pharmacol Res. 2022;186:106529. https:\/\/doi.org\/10.1016\/j.phrs.2022.106529.","journal-title":"Pharmacol Res"},{"issue":"12","key":"3775_CR30","doi-asserted-by":"publisher","first-page":"9606","DOI":"10.3390\/cimb45120601","volume":"45","author":"T Liu","year":"2023","unstructured":"Liu T, Du J, Cheng X, Wei J. Integrative analysis of the role of TP53 in human pan-cancer. Curr Issues Mol Biol. 2023;45(12):9606\u201333. https:\/\/doi.org\/10.3390\/cimb45120601.","journal-title":"Curr Issues Mol Biol"},{"key":"3775_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104058","volume":"188","author":"JM Hernandez-Martinez","year":"2023","unstructured":"Hernandez-Martinez JM, Rosell R, Arrieta O. Somatic and germline ATM variants in non-small-cell lung cancer: therapeutic implications. Crit Rev Oncol Hematol. 2023;188:104058. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104058.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3775_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.608300","volume":"10","author":"T Hou","year":"2020","unstructured":"Hou T, Jiang S, Wang Y, Xie Y, Zhang H, Feng Y, et al. Alpha thalassemia\/intellectual disability X-linked deficiency sensitizes non-small cell lung cancer to immune checkpoint inhibitors. Front Oncol. 2020;10:608300. https:\/\/doi.org\/10.3389\/fonc.2020.608300.","journal-title":"Front Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03775-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03775-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03775-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T13:45:36Z","timestamp":1767620736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03775-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3775"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03775-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a study undertaken in compliance with the Declaration of Helsinki. The study was approved by the Sixth People\u2019s Hospital of Chengdu [Number (No):2022-k (Research Project)-001].\u00a0Written informed consent was obtained from all individuals included in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}